

# HYPERURICEMIA AND GOUT: MANAGEMENT CHALLENGES AND SOLUTIONS

Supplement 5 to Volume 75, July 2008

[www.ccmj.org/ccjm\\_pdfs\\_supplements/gout.asp](http://www.ccmj.org/ccjm_pdfs_supplements/gout.asp)

## Supplement Editor

BRIAN F. MANDELL, MD, PhD

Cleveland Clinic

## Contents

<b>From the editor</b>	
<b>Confessions of a goutophile: Despite its treatability, gout remains a problem</b> . . . . .S1	<b>Epidemiology of gout</b> . . . . .S9
Brian F. Mandell, MD, PhD	Arthur L. Weaver, MD, MS
<b>The pathogenesis of gout</b> . . . . .S2	<b>The role of hyperuricemia and gout in kidney and cardiovascular disease</b> . . . . .S13
H. Ralph Schumacher, Jr, MD	N. Lawrence Edwards, MD
<b>Clinical manifestations of hyperuricemia and gout</b> . . . . .S5	<b>The gout diagnosis</b> . . . . .S17
Brian F. Mandell, MD, PhD	Robin K. Dore, MD
	<b>The practical management of gout</b> . . . . .S22
	H. Ralph Schumacher, Jr, MD, and Lan X. Chen, MD, PhD

This supplement is based on the proceedings of a symposium, “The Hyperuricemia and Gout Summit,” held October 5, 2007, in Scottsdale, Ariz. All faculty presentations at the symposium were developed by the presenting physicians themselves. The symposium was organized logistically by Fallon Medica LLC, a medical communication company. Fallon Medica transcribed audio recordings of the symposium presentations and forwarded the transcripts to the respective physician presenters, who developed the transcripts into the articles published here without assistance from undeclared contributors. All but one of the articles underwent formatting and nonsubstantive copyediting by Fallon prior to submission to *Cleveland Clinic Journal of Medicine*. The *Journal* had all articles peer reviewed to ensure independence and freedom from bias.

This supplement and the symposium on which it is based were supported by educational grants from TAP Pharmaceutical Products Inc.

Topics and editors of supplements to the *Cleveland Clinic Journal of Medicine* are determined by the *Journal's* editor-in-chief and staff. Supplement editors are chosen for their expertise in the topics discussed and are responsible for the scientific quality of supplements, including the review process. The *Journal* ensures that supplement editors and authors fully disclose any relationships with industry, including the supplement underwriter. For complete guidelines on grant-supported supplements to the *Journal*, please visit [www.ccmj.org/instructions\\_grant-supported\\_supplements.asp](http://www.ccmj.org/instructions_grant-supported_supplements.asp).

Copyright © 2008 The Cleveland Clinic Foundation. All rights reserved.  
The statements and opinions expressed in this supplement to the *Cleveland Clinic Journal of Medicine* are those of the authors and not necessarily of the Cleveland Clinic Foundation, its Board of Trustees, or TAP Pharmaceutical Products Inc. They do not necessarily represent formal practice guidelines in effect at Cleveland Clinic.  
The *Cleveland Clinic Journal of Medicine* [ISSN 0891-1150 (print), ISSN 1939-2869 (online)] is published 12 times yearly by the Cleveland Clinic Foundation.  
Subscription rates: U.S. and possessions: personal \$108; institutional \$134; single

copy/back issue \$20. Foreign: \$134; single copy/back issue \$20. Institutional (multiple-reader) rate applies to libraries, schools, hospitals, and federal, commercial, and private organizations. Individual subscriptions must be in the names of and paid by individuals.  
Postmaster address changes: *Cleveland Clinic Journal of Medicine*, NA32, 9500 Euclid Avenue, Cleveland, OH 44195. Subscription orders, editorial, reprint, and production offices (same address): (216) 444-2661 (phone); (216) 444-9385 (fax); [ccjm@ccf.org](mailto:ccjm@ccf.org) (e-mail); [www.ccmj.org](http://www.ccmj.org) (Web).  
Printed in USA.

**AMM** Association of Medical Media